Symbols / IBRX Stock $7.44 -9.16% ImmunityBio, Inc.

Healthcare • Biotechnology • United States • NMS
IBRX (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Richard Gerald Adcock
Exch · Country NMS · United States
Market Cap 7.68B
Enterprise Value 8.25B
Income -351.40M
Sales 113.29M
FCF (ttm) -213.36M
Book/sh -0.49
Cash/sh 0.24
Employees 684
Insider 10d —
IPO Jul 28, 2015
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -372.00
PEG —
P/S 67.82
P/B -15.03
P/C —
EV/EBITDA -34.30
EV/Sales 72.84
Quick Ratio 4.62
Current Ratio 5.10
Debt/Eq —
LT Debt/Eq —
EPS (ttm) -0.38
EPS next Y -0.02
EPS Growth —
Revenue Growth 4.07%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-11
Earnings (prior) 2026-02-23
ROA -36.17%
ROE —
ROIC —
Gross Margin 99.33%
Oper. Margin -168.95%
Profit Margin 0.00%
Shs Outstand 1.03B
Shs Float 377.71M
Insider Own 63.67%
Instit Own 17.00%
Short Float 37.06%
Short Ratio 6.18
Short Interest 140.33M
52W High 12.43
vs 52W High -40.14%
52W Low 1.83
vs 52W Low 306.56%
Beta 0.06
Impl. Vol. 48.97%
Rel Volume 0.60
Avg Volume 28.01M
Volume 16.85M
Target (mean) $14.80
Tgt Median $13.00
Tgt Low $11.00
Tgt High $23.00
# Analysts 5
Recom Strong_buy
Prev Close $8.19
Price $7.44
Change -9.16%
About

ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors; and 3M-052, a synthetic TLR7/8 agonist and 3M-052 formulations and related technology. The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeOne Medicines Ltd. It has license agreement with 3M Innovative Properties Company and Access to Advanced Health Institute. ImmunityBio, Inc. is based in San Diego, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$14.80
Mean price target
2. Current target
$7.44
Latest analyst target
3. DCF / Fair value
$-3.72
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$7.44
Low
$11.00
High
$23.00
Mean
$14.80

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-21 main D. Boral Capital Buy → Buy $23
2026-04-08 main D. Boral Capital Buy → Buy $23
2026-03-26 main D. Boral Capital Buy → Buy $23
2026-03-23 main D. Boral Capital Buy → Buy $23
2026-03-17 main D. Boral Capital Buy → Buy $23
2026-03-09 main D. Boral Capital Buy → Buy $23
2026-03-04 reit Piper Sandler Overweight → Overweight $12
2026-02-23 main D. Boral Capital Buy → Buy $23
2026-02-23 main HC Wainwright & Co. Buy → Buy $15
2026-02-19 main D. Boral Capital Buy → Buy $24
2026-02-17 main D. Boral Capital Buy → Buy $24
2026-01-26 main HC Wainwright & Co. Buy → Buy $10
2026-01-23 main D. Boral Capital Buy → Buy $24
2026-01-23 main BTIG Buy → Buy $9
2026-01-20 main Piper Sandler Overweight → Overweight $7
2026-01-20 main D. Boral Capital Buy → Buy $24
2026-01-16 main D. Boral Capital Buy → Buy $24
2026-01-13 main D. Boral Capital Buy → Buy $24
2025-12-16 main D. Boral Capital Buy → Buy $24
2025-12-12 main Jefferies Buy → Buy $9
News
RSS: Latest IBRX news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-31 SOON-SHIONG PATRICK Officer, Director and Beneficial Owner — 4,606,596 $5.43 $24,999,996
2026-02-24 SIMON BARRY J. M.D. Director — 75,000 $12.01 $900,788
2026-02-23 SIMON BARRY J. M.D. Director — 175,000 $9.25 $1,783,602
2026-02-23 SELECKY CHRISTOBEL E. Director — 25,000 $10.00 $250,000
2026-02-23 SELECKY CHRISTOBEL E. Director — 25,000 $2.98 $74,500
2026-02-20 SOON-SHIONG PATRICK Officer, Director and Beneficial Owner — 114,329 — —
2026-02-20 SIMON BARRY J. M.D. Director — 15,243 — —
2026-02-20 ADCOCK RICHARD Chief Executive Officer — 152,439 — —
2026-02-20 SACHS DAVID C Chief Financial Officer — 40,650 — —
2026-02-20 LAUER REGAN J Officer — 4,065 — —
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
113.29
+668.31%
14.74
+2270.58%
0.62
+159.17%
0.24
Operating Revenue
112.98
+698.46%
14.15
0.00
0.00
Cost Of Revenue
0.75
0.00
0.00
0.00
Reconciled Cost Of Revenue
0.75
0.00
0.00
0.00
Gross Profit
112.53
+663.21%
14.74
+2270.58%
0.62
+159.17%
0.24
Operating Expense
368.56
+2.68%
358.93
-0.85%
361.99
+3.17%
350.86
Research And Development
218.56
+14.94%
190.14
-18.17%
232.37
-6.36%
248.15
Selling General And Administration
150.00
-11.13%
168.78
+30.21%
129.62
+26.20%
102.71
Total Expenses
369.31
+2.89%
358.93
-0.85%
361.99
+3.17%
350.86
Operating Income
-256.03
+25.61%
-344.18
+4.75%
-361.36
-3.07%
-350.62
Total Operating Income As Reported
-256.03
+25.61%
-344.18
+4.99%
-362.25
-3.12%
-351.30
EBITDA
-223.56
+15.43%
-264.35
+44.76%
-478.58
-36.01%
-351.88
Normalized EBITDA
-282.76
+6.79%
-303.36
+29.51%
-430.36
-19.92%
-358.86
Reconciled Depreciation
15.53
-11.56%
17.55
-5.18%
18.51
+1.38%
18.26
EBIT
-239.08
+15.19%
-281.90
+43.29%
-497.09
-34.30%
-370.14
Total Unusual Items
59.20
+51.78%
39.01
+180.90%
-48.22
-790.70%
6.98
Total Unusual Items Excluding Goodwill
59.20
+51.78%
39.01
+180.90%
-48.22
-790.70%
6.98
Special Income Charges
0.00
0.00
+100.00%
-0.89
-30.10%
-0.68
Impairment Of Capital Assets
0.00
0.00
-100.00%
0.89
+30.10%
0.68
Net Income
-351.40
+15.03%
-413.56
+29.09%
-583.20
-40.00%
-416.57
Pretax Income
-351.61
+15.00%
-413.64
+29.16%
-583.89
-39.93%
-417.29
Net Non Operating Interest Income Expense
-109.84
+27.70%
-151.93
-18.38%
-128.34
-111.05%
-60.81
Interest Expense Non Operating
112.53
-14.59%
131.74
+51.77%
86.80
+84.12%
47.15
Net Interest Income
-109.84
+27.70%
-151.93
-18.38%
-128.34
-111.05%
-60.81
Interest Expense
112.53
-14.59%
131.74
+51.77%
86.80
+84.12%
47.15
Interest Income Non Operating
2.69
+12.04%
2.40
+178.10%
0.86
-68.13%
2.71
Interest Income
2.69
+12.04%
2.40
+178.10%
0.86
-68.13%
2.71
Other Income Expense
14.26
-82.71%
82.46
+187.55%
-94.19
-1506.84%
-5.86
Other Non Operating Income Expenses
-44.95
-203.43%
43.46
+213.09%
-38.43
-5120.92%
-0.74
Gain On Sale Of Security
59.20
+51.78%
39.01
+182.41%
-47.33
-717.75%
7.66
Tax Provision
-0.14
0.00
+100.00%
-0.04
-217.65%
0.03
Tax Rate For Calcs
0.00
0.00
-100.00%
0.00
-99.97%
0.00
Tax Effect Of Unusual Items
0.00
0.00
+100.00%
-0.00
-100.23%
1.47
Net Income Including Noncontrolling Interests
-351.47
+15.03%
-413.64
+29.15%
-583.85
-39.91%
-417.32
Net Income From Continuing Operation Net Minority Interest
-351.40
+15.03%
-413.56
+29.09%
-583.20
-40.00%
-416.57
Net Income From Continuing And Discontinued Operation
-351.40
+15.03%
-413.56
+29.09%
-583.20
-40.00%
-416.57
Net Income Continuous Operations
-351.47
+15.03%
-413.64
+29.15%
-583.85
-39.91%
-417.32
Minority Interests
0.07
-8.64%
0.08
-87.65%
0.66
-12.88%
0.75
Normalized Income
-410.60
+9.27%
-452.57
+15.40%
-534.98
-26.75%
-422.08
Net Income Common Stockholders
-351.40
+15.03%
-413.56
+29.09%
-583.20
-40.00%
-416.57
Diluted EPS
-0.38
+38.71%
-0.62
+46.09%
-1.15
-10.58%
-1.04
Basic EPS
-0.38
+35.59%
-0.59
+48.70%
-1.15
-10.58%
-1.04
Basic Average Shares
919.86
+31.92%
697.31
+37.09%
508.64
+27.19%
399.90
Diluted Average Shares
919.86
+31.33%
700.44
+37.71%
508.64
+27.19%
399.90
Diluted NI Availto Com Stockholders
-351.40
+15.03%
-413.56
+29.09%
-583.20
-40.00%
-416.57
Earnings From Equity Interest
0.00
0.00
+100.00%
-7.55
+37.65%
-12.11
Securities Amortization
—
—
-1.84
-224.09%
1.49
Total Other Finance Cost
—
22.59
-46.72%
42.40
+158.99%
16.37
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
501.90
+31.07%
382.93
-24.09%
504.45
+39.21%
362.36
Current Assets
314.88
+70.58%
184.59
-37.23%
294.08
+109.20%
140.58
Cash Cash Equivalents And Short Term Investments
242.82
+62.09%
149.81
-43.78%
266.46
+148.60%
107.18
Cash And Cash Equivalents
88.33
-38.41%
143.43
-45.97%
265.45
+153.68%
104.64
Other Short Term Investments
154.48
+2321.00%
6.38
+532.41%
1.01
-60.32%
2.54
Receivables
42.62
+1506.37%
2.65
-16.26%
3.17
+67.62%
1.89
Accounts Receivable
42.57
+1703.86%
2.36
0.00
—
Other Receivables
—
—
1.15
—
Inventory
0.91
-89.00%
8.27
0.00
—
Raw Materials
—
0.00
0.00
—
Work In Process
—
7.50
0.00
—
Finished Goods
—
0.77
0.00
—
Prepaid Assets
26.39
+17.06%
22.55
+3.30%
21.83
-23.69%
28.60
Other Current Assets
2.13
+63.85%
1.30
-50.36%
2.62
-9.45%
2.90
Total Non Current Assets
187.02
-5.71%
198.35
-5.71%
210.37
-5.15%
221.78
Net PPE
147.27
-13.60%
170.46
-6.66%
182.62
-3.60%
189.45
Gross PPE
259.76
-3.81%
270.05
+1.14%
267.00
+3.21%
258.70
Accumulated Depreciation
-112.48
-12.95%
-99.59
-18.03%
-84.38
-21.84%
-69.25
Properties
0.00
0.00
0.00
0.00
Buildings And Improvements
—
—
—
—
Machinery Furniture Equipment
3.92
+9.94%
3.56
+0.20%
3.56
-0.22%
3.56
Construction In Progress
86.43
+0.02%
86.42
+2.35%
84.44
+16.15%
72.69
Other Properties
96.27
-9.98%
106.94
+0.45%
106.46
-6.40%
113.73
Leases
73.14
+0.02%
73.13
+0.79%
72.55
+5.59%
68.71
Goodwill And Other Intangible Assets
13.95
-12.43%
15.93
-6.79%
17.09
-14.55%
20.00
Goodwill
0.91
+0.00%
0.91
—
—
Other Intangible Assets
13.04
-13.18%
15.02
-12.11%
17.09
-14.55%
20.00
Investments And Advances
—
0.00
-100.00%
0.89
+6.07%
0.84
Long Term Equity Investment
—
—
—
0.84
Other Investments
—
—
—
4.86
Other Non Current Assets
18.42
+281.52%
4.83
+67.60%
2.88
-40.74%
4.86
Total Liabilities Net Minority Interest
1,001.47
+14.97%
871.06
-20.11%
1,090.39
+34.26%
812.18
Current Liabilities
61.75
+12.39%
54.94
-5.73%
58.28
-88.36%
500.86
Payables And Accrued Expenses
31.08
-1.03%
31.40
-9.58%
34.73
-25.43%
46.57
Payables
7.38
+7.00%
6.90
-33.23%
10.33
-57.81%
24.48
Accounts Payable
6.98
+3.76%
6.72
-26.86%
9.20
-56.25%
21.02
Current Accrued Expenses
23.70
-3.30%
24.50
+0.43%
24.40
+10.47%
22.09
Pensionand Other Post Retirement Benefit Plans Current
20.07
+33.56%
15.03
-14.59%
17.59
-2.86%
18.11
Current Debt And Capital Lease Obligation
7.54
+0.92%
7.47
+42.37%
5.24
-98.79%
434.55
Current Debt
—
—
—
431.90
Other Current Borrowings
—
—
—
431.90
Current Capital Lease Obligation
7.54
+0.92%
7.47
+42.37%
5.24
+97.89%
2.65
Other Current Liabilities
3.07
+192.67%
1.05
+46.65%
0.72
-56.02%
1.63
Total Non Current Liabilities Net Minority Interest
939.72
+15.14%
816.12
-20.93%
1,032.11
+231.53%
311.31
Long Term Debt And Capital Lease Obligation
510.54
+2.79%
496.70
-31.16%
721.48
+149.46%
289.22
Long Term Debt
477.09
+3.29%
461.88
-32.23%
681.54
+182.48%
241.27
Long Term Capital Lease Obligation
33.45
-3.95%
34.82
-12.82%
39.94
-16.70%
47.95
Non Current Deferred Liabilities
—
—
—
—
Non Current Deferred Taxes Liabilities
—
—
—
—
Other Non Current Liabilities
325.04
+14.16%
284.72
+81.90%
156.52
+34150.33%
0.46
Stockholders Equity
-500.47
-2.32%
-489.10
+16.68%
-586.99
-31.22%
-447.33
Common Stock Equity
-500.47
-2.32%
-489.10
+16.68%
-586.99
-31.22%
-447.33
Capital Stock
0.10
+18.82%
0.09
+26.87%
0.07
+59.52%
0.04
Common Stock
0.10
+18.82%
0.09
+26.87%
0.07
+59.52%
0.04
Share Issued
1,011.96
+18.63%
853.07
+27.13%
671.03
+59.11%
421.73
Ordinary Shares Number
1,011.80
+18.63%
852.90
+27.13%
670.87
+59.14%
421.57
Treasury Shares Number
0.16
+0.00%
0.16
+0.00%
0.16
+0.00%
0.16
Additional Paid In Capital
3,197.12
+10.82%
2,884.87
+21.49%
2,374.62
+22.98%
1,930.94
Retained Earnings
-3,726.65
-10.41%
-3,375.25
-13.96%
-2,961.68
-24.52%
-2,378.49
Gains Losses Not Affecting Retained Earnings
28.96
+2317.03%
1.20
+11880.00%
0.01
-94.54%
0.18
Minority Interest
0.90
-7.64%
0.97
-7.71%
1.05
+142.12%
-2.49
Other Equity Adjustments
28.96
+2317.03%
1.20
+11880.00%
0.01
-94.54%
0.18
Total Equity Gross Minority Interest
-499.57
-2.34%
-488.13
+16.69%
-585.94
-30.26%
-449.82
Total Capitalization
-23.38
+14.13%
-27.22
-128.79%
94.55
+145.89%
-206.06
Working Capital
253.12
+95.25%
129.64
-45.02%
235.80
+165.45%
-360.28
Invested Capital
-23.38
+14.13%
-27.22
-128.79%
94.55
-58.14%
225.84
Total Debt
518.08
+2.76%
504.17
-30.62%
726.72
+0.41%
723.77
Net Debt
388.76
+22.08%
318.45
-23.47%
416.08
-26.81%
568.53
Capital Lease Obligations
40.98
-3.09%
42.29
-6.41%
45.19
-10.70%
50.60
Net Tangible Assets
-514.42
-1.86%
-505.03
+16.40%
-604.08
-29.26%
-467.33
Tangible Book Value
-514.42
-1.86%
-505.03
+16.40%
-604.08
-29.26%
-467.33
Available For Sale Securities
—
—
0.89
+6.07%
0.84
Current Notes Payable
—
—
—
—
Derivative Product Liabilities
104.14
+200.16%
34.70
-77.49%
154.10
+612.25%
21.64
Duefrom Related Parties Current
0.05
-84.30%
0.29
-85.49%
2.02
+6.83%
1.89
Dueto Related Parties Current
0.40
+132.95%
0.17
-84.77%
1.14
-67.25%
3.47
Investmentin Financial Assets
—
0.00
-100.00%
0.89
+6.07%
0.84
Non Current Note Receivables
7.38
+3.51%
7.13
+3.65%
6.88
+3.77%
6.63
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-304.94
+22.06%
-391.24
-6.67%
-366.76
-8.67%
-337.51
Cash Flow From Continuing Operating Activities
-304.94
+22.06%
-391.24
-6.67%
-366.76
-8.67%
-337.51
Net Income From Continuing Operations
-351.47
+15.03%
-413.64
+29.15%
-583.85
-39.91%
-417.32
Depreciation Amortization Depletion
15.53
-11.56%
17.55
-5.18%
18.51
+1.38%
18.26
Depreciation And Amortization
15.53
-11.56%
17.55
-5.18%
18.51
+1.38%
18.26
Other Non Cash Items
90.58
+275.31%
24.13
-74.23%
93.64
+165.19%
35.31
Stock Based Compensation
36.81
+6.90%
34.43
-29.96%
49.16
+22.36%
40.18
Asset Impairment Charge
14.02
0.00
-100.00%
0.89
-56.01%
2.01
Deferred Tax
—
—
—
-0.00
Deferred Income Tax
—
—
—
-0.00
Operating Gains Losses
-53.32
-59.49%
-33.43
-167.39%
49.61
+468.57%
-13.46
Gain Loss On Investment Securities
-53.32
-59.49%
-33.43
-167.39%
49.61
+468.57%
-13.46
Unrealized Gain Loss On Investment Securities
0.00
-100.00%
0.63
-60.28%
1.59
-62.03%
4.19
Change In Working Capital
-54.33
-179.73%
-19.42
-607.37%
3.83
+147.84%
-8.00
Change In Receivables
-40.21
-1603.86%
-2.36
0.00
0.00
Changes In Account Receivables
-40.21
-1603.86%
-2.36
0.00
0.00
Change In Inventory
-6.33
+23.54%
-8.27
0.00
0.00
Change In Prepaid Assets
-4.86
-385.20%
1.70
-71.42%
5.96
+135.98%
-16.56
Change In Payables And Accrued Expense
2.99
+164.04%
-4.67
-2294.84%
0.21
-98.24%
12.10
Change In Accrued Expense
3.18
+311.14%
-1.51
-122.54%
6.69
+63.07%
4.10
Change In Payable
-0.19
+94.00%
-3.17
+51.10%
-6.48
-180.95%
8.00
Change In Account Payable
-0.19
+94.00%
-3.17
+51.10%
-6.48
-180.95%
8.00
Change In Other Working Capital
0.48
-37.48%
0.76
+167.58%
-1.13
+7.84%
-1.23
Change In Other Current Assets
0.80
+172.47%
-1.11
-162.81%
1.76
-11.71%
2.00
Change In Other Current Liabilities
-7.21
-31.74%
-5.47
-83.78%
-2.98
+31.05%
-4.32
Investing Cash Flow
-149.80
-1123.26%
-12.25
+59.81%
-30.47
-211.62%
27.30
Cash Flow From Continuing Investing Activities
-149.80
-1123.26%
-12.25
+59.81%
-30.47
-211.62%
27.30
Net PPE Purchase And Sale
-3.85
+44.16%
-6.89
+77.48%
-30.58
+60.87%
-78.16
Purchase Of PPE
-3.85
+44.16%
-6.89
+77.48%
-30.58
+60.87%
-78.16
Sale Of PPE
—
—
0.00
0.00
Capital Expenditure
-4.25
+38.27%
-6.89
+77.48%
-30.58
+69.23%
-99.39
Net Investment Purchase And Sale
-145.55
-3239.81%
-4.36
-3922.81%
0.11
-99.91%
127.69
Purchase Of Investment
-241.37
-71.23%
-140.97
-1260.93%
-10.36
+69.81%
-34.31
Sale Of Investment
95.82
-29.85%
136.61
+1204.50%
10.47
-93.54%
162.00
Net Business Purchase And Sale
—
0.00
0.00
+100.00%
-1.00
Purchase Of Business
—
0.00
0.00
+100.00%
-1.00
Net Intangibles Purchase And Sale
-0.41
0.00
0.00
+100.00%
-21.23
Purchase Of Intangibles
-0.41
0.00
0.00
+100.00%
-21.23
Net Other Investing Changes
—
-1.00
—
—
Financing Cash Flow
400.24
+42.12%
281.63
-49.56%
558.34
+139.00%
233.61
Cash Flow From Continuing Financing Activities
400.24
+42.12%
281.63
-49.56%
558.34
+139.00%
233.61
Net Issuance Payments Of Debt
2.86
+4562.50%
-0.06
-100.02%
258.62
+48.58%
174.07
Issuance Of Debt
2.88
0.00
-100.00%
258.70
+48.57%
174.12
Repayment Of Debt
-0.03
+56.25%
-0.06
+16.88%
-0.08
-32.76%
-0.06
Long Term Debt Issuance
0.00
0.00
-100.00%
258.70
+48.57%
174.12
Long Term Debt Payments
-0.03
+56.25%
-0.06
+16.88%
-0.08
-32.76%
-0.06
Net Long Term Debt Issuance
-0.03
+56.25%
-0.06
-100.02%
258.62
+48.58%
174.07
Short Term Debt Issuance
2.88
0.00
0.00
-100.00%
174.12
Net Short Term Debt Issuance
2.88
0.00
0.00
-100.00%
174.12
Net Common Stock Issuance
400.56
+259.71%
111.36
+10.74%
100.56
+66.42%
60.43
Common Stock Payments
—
—
—
—
Repurchase Of Capital Stock
—
—
—
—
Proceeds From Stock Option Exercised
-2.04
-102.79%
73.38
+1047.83%
6.39
+1279.52%
-0.54
Net Other Financing Charges
-1.13
-101.17%
96.96
-49.70%
192.76
+56962.54%
-0.34
Changes In Cash
-54.50
+55.28%
-121.85
-175.63%
161.11
+310.33%
-76.60
Effect Of Exchange Rate Changes
0.01
+165.22%
-0.02
+92.12%
-0.29
-202.82%
0.28
Beginning Cash Position
143.91
-45.85%
265.79
+153.21%
104.97
-42.10%
181.28
End Cash Position
89.43
-37.86%
143.91
-45.85%
265.79
+153.21%
104.97
Free Cash Flow
-309.19
+22.34%
-398.12
-0.20%
-397.34
+9.05%
-436.90
Interest Paid Supplemental Data
71.32
-22.74%
92.32
+19.60%
77.19
+117.80%
35.44
Income Tax Paid Supplemental Data
0.00
-100.00%
0.01
+87.50%
0.01
+300.00%
0.00
Amortization Of Securities
-2.75
-84.35%
-1.49
-986.86%
-0.14
-110.39%
1.32
Common Stock Issuance
400.56
+259.71%
111.36
+10.74%
100.56
+66.42%
60.43
Earnings Losses From Equity Investments
—
—
—
—
Issuance Of Capital Stock
400.56
+259.71%
111.36
+10.74%
100.56
+66.42%
60.43
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category